In:
World Journal of Gastroenterology, Baishideng Publishing Group Inc., Vol. 30, No. 8 ( 2024-2-28), p. 833-842
Abstract:
The population of non-alcoholic fatty liver disease (NAFLD) patients along with relevant advanced liver disease is projected to continue growing, because currently no medications are approved for treatment. Fecal microbiota transplantation (FMT) is believed a novel and promising therapeutic approach based on the concept of the gut-liver axis in liver disease. There has been an increase in the number of pre-clinical and clinical studies evaluating FMT in NAFLD treatment, however, existing findings diverge on its effects. Herein, we briefly summarized the mechanism of FMT for NAFLD treatment, reviewed randomized controlled trials for evaluating its efficacy in NAFLD, and proposed the prospect of future trials on FMT.
Type of Medium:
Online Resource
ISSN:
1007-9327
DOI:
10.3748/wjg.v30.i8.833
Language:
Unknown
Publisher:
Baishideng Publishing Group Inc.
Publication Date:
2024
detail.hit.zdb_id:
2084831-6